Morning Trend | IMMUNEONCO-B shows increased volume at the bottom, is there a chance for capital to flow back?

On January 21st, at the close, IMMUNEONCO-B (1541.HK) operated close to the lower Bollinger Band throughout the day, with significant trading volume clearly dominated by selling pressure. The innovative drug sector has been generally sluggish recently, with frequent rotation of industry hotspots and a strong atmosphere of wait-and-see from outside investors, with no signs of capital clustering. There have been no major advancements in new drugs or announcements of capital cooperation from the company, and the main players in the sector prefer leading companies with significant scientific breakthroughs. The issuance of new funds or industry policy support has yet to materialize, and market defensive sentiment remains high. On the technical side, the MACD remains in a very low area, with 4.88 yuan becoming a key support level. If this round of increased volume fails to hold, it may trigger a new technical low, increasing asset allocation pressure. There are occasional short-term buying spikes during the day, but the actions of main funds are not unified, primarily focusing on short-term low-buying and quick-selling speculative plays. In terms of medium to short-term strategy, attention should be paid to industry policies and new developments from the company, with a focus on the dynamic rotation brought about by sector hotspot surges in capital flow. Continuous recovery in trading volume or event-driven factors is essential for the sector's warming. Although a rebound from oversold conditions is possible, its sustainability is questionable, and right-side traders should keep their positions at a reasonable level to avoid blindly increasing high-risk operations